MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Earnings & Estimates
USA - NASDAQ:MLTX - KY61559X1045 - Common Stock
9.885 USD
+0.37 (+3.83%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 360.34% | N/A 167.03% | N/A 65.75% | N/A -2.24% | N/A 24.12% | |||||||
| EBITDA YoY % growth | N/A | N/A | -53.58M | -65.05M -21.41% | -54.11M 16.82% | -141.706M -161.89% | N/A -69.11% | N/A -21.12% | N/A 20.19% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -105.76K | -53.58M -50,561.88% | -65.06M -21.43% | -54.123M 16.81% | -143.091M -164.38% | N/A -66.77% | N/A -21.72% | N/A -11.72% | N/A 81.62% | N/A 617.68% | N/A 133.74% | N/A -48.99% | N/A 43.87% | ||
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -0.76 49.48% | -1.89 -148.68% | N/A -77.76% | N/A -10.51% | N/A 6.77% | N/A 33.55% | N/A 85.70% | N/A 696.90% | N/A 128.31% | N/A 38.34% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.90 -60.02% | -0.91 -26.47% | -0.96 -52.19% | -0.99 -14.31% | -0.99 -10.41% | -1.03 -12.85% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | -62.498M -45.25% | -63.579M -31.92% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -63.633M -47.60% | -64.599M -30.29% | -68.504M -44.26% | -69.909M -15.17% | -69.309M -8.92% | -71.604M -10.84% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.87 -123.08% | -0.74 | -0.13 | -18.26% |
| Q1 2025 Q2Q % growth | -0.63 -186.36% | -0.77 | 0.14 | 17.89% |
| Q4 2024 Q2Q % growth | -0.72 -500.00% | -0.61 | -0.11 | -18.11% |
| Q3 2024 Q2Q % growth | -0.56 -211.11% | -0.44 | -0.12 | -26.10% |
| Q2 2024 Q2Q % growth | -0.39 -69.57% | -0.28 | -0.11 | -37.92% |
| Q1 2024 Q2Q % growth | -0.22 4.35% | -0.20 | -0.02 | -11.55% |
| Q4 2023 Q2Q % growth | -0.12 61.29% | -0.23 | 0.11 | 48.88% |
| Q3 2023 Q2Q % growth | -0.18 33.33% | -0.23 | 0.05 | 22.46% |
| Q2 2023 Q2Q % growth | -0.23 32.35% | -0.27 | 0.04 | 15.13% |
| Q1 2023 Q2Q % growth | -0.23 | -0.32 | 0.09 | 27.32% |
| Q4 2022 Q2Q % growth | -0.31 | -0.33 | 0.02 | 7.18% |
| Q3 2022 Q2Q % growth | -0.27 | -0.33 | 0.06 | 17.45% |
| Q2 2022 Q2Q % growth | -0.34 | -0.55 | 0.21 | 38.27% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -1.37% | -18.47% | -0.13% | -14.67% |
| Revenue | N/A | N/A | N/A | N/A |